Imatinib was the first commercially successful BcrAbl inhibitor, showing an 80% response rate in chronic myeloid leukemia (CML), outperforming the prior therapeutic options and turning CML into a manageable condition [3]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.